Skip to main content
RXD logo

ProShares - UltraShort Health Care (RXD) Fund Overview

Educational signal · not a buy or sell recommendation · How to read this

$15.33 +$0.0582 (+0.38%)
Vol: 3.8K|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

ProShares - UltraShort Health Care (RXD) trades at $15.33. ProShares UltraShort Health Care is an exchange-traded fund (ETF) that seeks to deliver twice the inverse of the daily performance of the S&P Health Care Select Sector Index. Sector: Financials.

Price as of · Last analyzed: Mar 18, 2026
ProShares UltraShort Health Care is an exchange-traded fund (ETF) that seeks to deliver twice the inverse of the daily performance of the S&P Health Care Select Sector Index. The fund provides investors with a way to potentially profit from short-term declines in the health care sector.

Analyst Coverage for RXD: RXD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

▶ Watch the RXD film Every key number, told as a short cinematic story — just press play. ~2 min

ProShares - UltraShort Health Care (RXD) Financial Services Profile

IPO Year2007

ProShares UltraShort Health Care (RXD) is a geared ETF providing -2x daily exposure to the S&P Health Care Select Sector Index, appealing to sophisticated investors seeking short-term, inverse exposure to the health care sector. It offers a tactical tool for hedging or potentially profiting from anticipated downturns in the health care market.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 18, 2026

What Is the Investment Thesis for RXD?

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

ProShares UltraShort Health Care (RXD) presents a tactical opportunity for investors with a bearish outlook on the health care sector. The fund's -2x leverage offers the potential for amplified gains when the S&P Health Care Select Sector Index declines. However, this leverage also magnifies losses if the index rises. Key considerations include the fund's daily reset feature, which can lead to performance erosion over longer holding periods, particularly in volatile markets. Investors should closely monitor health care sector trends, regulatory changes, and economic factors that could impact the index. RXD is best suited for short-term trading strategies and hedging purposes, rather than long-term investment.

Based on FMP financials and quantitative analysis

RXD Key Highlights

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

RXD seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the S&P Health Care Select SectorSM Index.

  • The fund is designed for sophisticated investors with a high-risk tolerance and a short-term trading horizon.
  • RXD offers intraday liquidity, allowing investors to buy and sell shares throughout the trading day.
  • Due to the leveraged nature of the fund, its performance can deviate significantly from the underlying index over longer periods, especially in volatile markets.
  • The fund's beta is -1.09, indicating an inverse correlation with the market.

Who Are RXD's Competitors?

RXD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
BENJ Horizon Landmark ETF $53.31 +0.03% $269M —
BLK BlackRock, Inc. $1059.63 -0.44% $164B 51 5-pillar
BX Blackstone Inc. $111.74 -0.45% $135B 68 5-pillar
APOS Apollo Global Management, Inc. $25.59 -0.23% $74.8B 56 5-pillar
BAM Brookfield Asset Management $44.85 +0.65% $71.6B 57 5-pillar
AMP Ameriprise Financial, Inc. $490.91 -0.79% $44.1B 77 5-pillar
ARES Ares Management Corporation $117.55 +0.84% $38.6B 57 5-pillar
TROW T. Rowe Price Group, Inc. $104.62 -1.14% $22.4B 80 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RXD's Key Strengths?

Leveraged inverse exposure provides the potential for high returns in a declining health care market.

  • Intraday liquidity allows for flexible trading strategies.
  • Established brand recognition in the ETF market.

What Are RXD's Weaknesses?

Leverage magnifies losses if the health care sector rises.

  • Daily reset can lead to performance erosion over longer periods.
  • High expense ratio compared to non-leveraged ETFs.

What Are the Key Risks for RXD?

Unexpected rallies in the health care sector leading to significant losses.

  • Changes in regulations governing leveraged ETFs.
  • High expense ratio compared to non-leveraged ETFs.
  • Daily reset leading to performance erosion over longer periods.

What Are RXD's Competitive Advantages?

  • First-mover advantage in offering leveraged inverse exposure to the S&P Health Care Select Sector Index.
  • Established brand recognition in the ETF market.
  • Proprietary trading strategies and risk management expertise.

What Does RXD Do?

ProShares UltraShort Health Care (RXD) is designed for sophisticated investors seeking to achieve a multiple of the inverse of the daily performance of a specific index. Specifically, RXD aims to deliver two times the inverse (-2x) of the daily performance of the S&P Health Care Select Sector Index, before fees and expenses. This fund is not intended for long-term investment and is best suited for investors with a high-risk tolerance and a short-term trading horizon. The S&P Health Care Select Sector Index represents the health care sector of the S&P 500, including companies from industries such as pharmaceuticals, biotechnology, health care equipment, and health care services. RXD provides a way for investors to potentially profit from a decline in the value of these companies, using a leveraged inverse strategy. As an ETF, RXD offers intraday liquidity, allowing investors to buy and sell shares throughout the trading day. However, due to the leveraged nature of the fund, its performance can deviate significantly from the underlying index over longer periods, especially in volatile markets. Investors should carefully monitor their positions and understand the risks associated with leveraged and inverse ETFs.

What Products and Services Does RXD Offer?

  • Provides leveraged inverse exposure to the S&P Health Care Select Sector Index.
  • Offers a way to potentially profit from short-term declines in the health care sector.
  • Designed for sophisticated investors with a high-risk tolerance.
  • Trades like a stock on major exchanges.
  • Offers intraday liquidity.
  • Resets daily, which can lead to performance erosion over longer periods.

How Does RXD Make Money?

  • RXD generates revenue through management fees charged to investors.
  • The fund's performance is directly linked to the performance of the S&P Health Care Select Sector Index.
  • The fund uses a leveraged inverse strategy to amplify its returns.

What Industry Does RXD Operate In?

The asset management industry is characterized by intense competition, with firms vying for market share based on investment performance, fees, and product innovation. ETFs like RXD offer specialized exposure to specific sectors or investment strategies, catering to investors with diverse risk appetites and investment objectives. The health care sector, in particular, is subject to regulatory scrutiny and market volatility, creating opportunities for inverse ETFs like RXD to capitalize on short-term declines. The industry faces ongoing pressure to reduce fees and improve transparency, driving innovation in product design and distribution.

Who Are RXD's Key Customers?

  • Sophisticated investors
  • High-risk tolerance traders
  • Investors seeking short-term exposure to the health care sector
  • Investors hedging their portfolios against potential declines in health care stocks
Model self-rating on this text: 73% (not a measure of the evidence) Updated: Mar 18, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
  • ● This is an etf, not an operating company

MoonshotScore History

Recorded daily since 2026-08-23 · 41 snapshots

2026-08-23 47
2026-08-31 47
2026-09-08 47
2026-09-16 47
2026-09-24 47
2026-10-04 47

What changed?

The score has stayed at 47.

Over the same 30 days the stock moved +7.3%.

RXD Financials

Bull Case vs Bear Case

Bull Case

  • Leveraged inverse exposure provides the potential for high returns in a declining health care market.
  • Intraday liquidity allows for flexible trading strategies.
  • Established brand recognition in the ETF market.
  • Upcoming: Potential for increased volatility in the health care sector due to upcoming regulatory changes.

Bear Case

  • Leverage magnifies losses if the health care sector rises.
  • Daily reset can lead to performance erosion over longer periods.
  • High expense ratio compared to non-leveraged ETFs.
  • Potential: Unexpected rallies in the health care sector leading to significant losses.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

RXD Latest News

No recent news available for RXD.

RXD Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RXD.

Price Targets

Wall Street price target analysis for RXD.

RXD MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RXD; grades run from A+ (80-100) to F (below 30).

RXD Financials Stock FAQ

What are the main risks for RXD?

The main risks for RXD stem from its leveraged inverse structure. The fund's -2x leverage magnifies both gains and losses, making it highly sensitive to short-term market movements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Leveraged and inverse ETFs are complex financial instruments and are not suitable for all investors.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis